Suppr超能文献

[接受美沙酮治疗患者的驾驶适宜性/驾驶能力]

[Driving fitness/driving capacity of patients treated with methadone].

作者信息

Hauri-Bionda R, Bär W, Friedrich-Koch A

机构信息

Institut für Rechtsmedizin, Universität Zürich-Irchel.

出版信息

Schweiz Med Wochenschr. 1998 Oct 10;128(41):1538-47.

PMID:9816613
Abstract

To answer the question whether or not therapeutic methadone doses significantly reduce traffic-related performance of drivers on medically supervised methadone programmes, 34 methadone substitution patients, all of them volunteers, were subjected to a test series: the focus of the study was a psychophysical test battery consisting of 10 individual performance tests to assess essential functions with regard to driving ability, such as concentration, attention, reaction capability, memory, perception and sensorimotor coordination. In evaluating the results of the psychophysical tests, multiple drug use and subjective methadone influence at the time of the examination were taken into consideration but current methadone blood level was neglected. The results were compared to those of a control group. The methadone group (n = 34) consisted of 25 men and 9 women aged between 18 and 38. At the time of the study, the majority of the test persons (29) were on low dosage methadone maintenance (up to 60 mg/day). In the urine samples of approximately 2/3 of the test persons, evidence was found for multiple drug use together with other psychotropic substances, the most frequent (14) being cannabis metabolites. Referring to their driving practices, a mere 4 out of 29 drivers had not committed any driving offences. A comparison of the psychophysical performance of the whole methadone group (n = 34) with a control group demonstrated that the methadone substitution patients achieved rather lower results in almost all variables. These performance deficits were particularly conspicuous in sustained attention, sensorimotor coordination and reaction capability. 12 "methadone only" participants, i.e. methadone probands without any additional consumption of psychotropic substances showed-partly considerably-better performance than the methadone group as a whole and also achieved normal results in relation to the test norm. Nevertheless, once again, results tended to be of lower level in comparison to the control group. "Methadone only" substitution patients, in particular those volunteers without a current subjective methadone influence-reached practically the same results as the corresponding control subjects, or at least average results based on test norm. However, the study revealed distinctive performance impairment (e.g. in sustained attention, reaction capability) when other psychotropic substances (including alcohol and cannabis!) were taken as well during the subjective methadone phase. The performance deficits were predominantly caused by a slowing down of reactions. Our study illustrates that, under certain conditions, long-term methadone maintenance under strict medical supervision does not have any significant unfavourable impact on the psychophysical performances in driving ability as examined in this study. Thus, these research findings support the previous Zurich experiences, according to which driving ability--and in the end also driving aptitude--of the methadone substitution patients does not depend on the methadone therapy itself, nor on the amount of the daily methadone intake. In making the final medical judgement on driving ability, the presence of a mixed drug use and the personality of the person in question are of far greater importance.

摘要

为了回答在医学监督下的美沙酮治疗方案中,治疗剂量的美沙酮是否会显著降低驾驶员与交通相关的表现这一问题,对34名美沙酮替代治疗患者(均为志愿者)进行了一系列测试:该研究的重点是一个心理生理测试组合,包括10项个体表现测试,以评估与驾驶能力相关的基本功能,如注意力、专注力、反应能力、记忆力、感知力和感觉运动协调能力。在评估心理生理测试结果时,考虑了检查时的多种药物使用情况和美沙酮的主观影响,但忽略了当前的美沙酮血液水平。将结果与对照组进行比较。美沙酮组(n = 34)由25名男性和9名女性组成,年龄在18至38岁之间。在研究时,大多数测试者(29人)接受低剂量美沙酮维持治疗(每日剂量高达60毫克)。在大约三分之二测试者的尿液样本中,发现了与其他精神活性物质一起使用多种药物的证据,最常见的(14人)是大麻代谢物。就他们的驾驶行为而言,29名驾驶员中只有4人没有任何驾驶违规行为。将整个美沙酮组(n = 34)的心理生理表现与对照组进行比较表明,美沙酮替代治疗患者在几乎所有变量上的结果都相当低。这些表现缺陷在持续注意力、感觉运动协调和反应能力方面尤为明显。12名“仅使用美沙酮”的参与者,即没有额外使用任何精神活性物质的美沙酮受试者,其表现部分相当出色——比整个美沙酮组要好,并且相对于测试标准也取得了正常结果。然而,与对照组相比,结果再次趋于较低水平。“仅使用美沙酮”的替代治疗患者,特别是那些没有当前美沙酮主观影响的志愿者,实际上取得了与相应对照组相同的结果,或者至少是基于测试标准的平均结果。然而,研究发现,在主观美沙酮阶段同时使用其他精神活性物质(包括酒精和大麻!)时,会出现明显的表现受损(如在持续注意力、反应能力方面)。表现缺陷主要是由反应速度减慢引起的。我们的研究表明,在某些条件下,在严格的医学监督下进行长期美沙酮维持治疗,对本研究中所检测的驾驶能力的心理生理表现没有任何显著的不利影响。因此,这些研究结果支持了苏黎世先前的经验,即美沙酮替代治疗患者的驾驶能力——最终还有驾驶资质——既不取决于美沙酮治疗本身,也不取决于每日美沙酮摄入量。在对驾驶能力做出最终医学判断时,多种药物使用情况和相关人员的个性更为重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验